Randomized Phase 3, Multicenter, Open-Label Study Comparing Evofosfamide (EVO) in Combination with Doxorubicin (D) versus D Alone in Patients with Advanced Soft-Tissue Sarcoma (STS): Study TH-CR-406/SARC021

Conference Correspondents

This randomized phase 3 study compared the efficacy and safety of evofosfamide (EVO) plus doxorubicin (D) with D alone in patients with locally advanced unresectable or metastatic STS previously untreated with chemotherapy for advanced disease. Patients on EVO+D could receive EVO alone after 6 cycles. The primary end point was overall survival (OS). Secondary end points were progression-free survival (PFS), overall response rate (ORR), and safety.

From September 2011 to January 2014, 640 patients were randomized: 317 EVO+D, 323 D; 621 patients were treated. Baseline characteristics were balanced. The median age was 59 years (range, 18-89 years); 57% ECOG 0; 36% leiomyosarcoma, 17% liposarcoma, and 12% undifferentiated pleomorphic sarcoma.

The primary end point, OS, was not met. Median OS was 18.4 months for EVO+D and 19.0 months for D alone. ORR was 28% and 18%, respectively. Median PFS was 6.3 months and 6.0 months, respectively.

The most common grade 3 to 5 adverse events (AEs) were anemia (35%), neutropenia (33%), and leukopenia (18%). Febrile neutropenia occurred in 18% of patients taking EVO+D and 11% taking D. AEs leading to death occurred in 2.6% and 1.0%, respectively.  

Although ORR was significantly higher, the combination of EVO+D did not significantly improve OS or PFS. The safety profile was consistent with previous reports.

Tap W, et al. CTOS 2016. Abstract 2554705. P2 Poster 94.

Related Articles

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: